Threat actors abused trusted Trivy distribution channels to inject credential‑stealing malware into CI/CD pipelines worldwide ...

Ricursive Intelligence, a startup building an AI system to design and automatically improve AI chips, has raised $300 million at a $4 billion valuation. The company said Monday the round was led by ...

Recursion Pharmaceuticals is currently showing a mixed technical picture for traders. The stock is trading 12.2% above its 20-day SMA, which suggests some short-term strength, but it’s struggling ...

Recursion Pharmaceuticals stock jumped 16% on October 8, 2025, reaching around $6.08 after falling 5.4% the previous day on broader market weakness. The company reported Q2 2025 revenue of $19.2 ...

To continue reading this content, please enable JavaScript in your browser settings and refresh this page. There are specific places that remind us of an important ...

Good afternoon, everyone, and welcome to Morgan Stanley Global Healthcare Conference. I'm Sean Laaman, Head of U.S. Mid-cap Biotech Equity Research here at the firm. Before we begin, for important ...

Recent discussions on X about Recursion Pharmaceuticals (RXRX) have centered around the company's notable stock price surge of 14% over the past month, a performance that stands out against a ...

In the latest trading session, Recursion Pharmaceuticals (RXRX) closed at $5.27, marking a +1.15% move from the previous day. The stock's performance was ahead of the S&P 500's daily gain of 0.83%. At ...